ArticleScientific reports2026
The association between time in range with sarcopenia and its components in older patients with type 2 diabetes mellitus.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Time in range (TIR) is a new marker for blood glucose management, but its relationship with sarcopenia and its components requires further investigation. This study aims to investigate the association between TIR and sarcopenia and its components in older patients with type 2 diabetes mellitus (T2DM). This cross-sectional study included 310 hospitalized patients aged ≥ 60 years with T2DM. Continuous glucose monitoring (CGM) was used to assess TIR, and sarcopenia was diagnosed according to the 2019 criteria of the Asian Working Group on Sarcopenia, including indicators such as skeletal muscle mass index (SMI), handgrip strength, and physical performance. The relationships between TIR and sarcopenia and its components were analyzed using a logistic regression model, a linear regression model, and a restricted cubic spline model. The prevalence of sarcopenia was 32.3%. After adjusting for multiple factors, each 10% increase in TIR was associated with a 17% reduction in sarcopenia risk (odds ratio [OR] and 95% confidence interval [CI] = 0.83 [0.74-0.93], P = 0.001). Patients with TIR ≥ 70% had a 62% lower risk of sarcopenia compared to those with TIR < 50% (OR and 95%CI: 0.38 [0.19-0.74], P = 0.005). TIR showed a linear positive correlation with SMI and a nonlinear correlation with handgrip strength; however, it was not significantly associated with physical performance. Higher TIR is associated with higher muscle mass and handgrip strength, as well as a lower incidence of sarcopenia. For older adults with type 2 diabetes who have a low TIR, caution should be exercised regarding their elevated risk of developing sarcopenia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.